Estuary Biotherapeutics
Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.
$93MSeries A
Participant4C
4BIO Capital
Activity from announced rounds
Activity in this selectionOct 31, 2026 · Oct 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $111M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionUndecimal Bio
Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease.
$18MSeed
Lead